<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information for the period ended
September 30, 1997, restated to reflect the combined results of Incyte
Pharmaceuticals, Inc. and Synteni, Inc.
</LEGEND>
<RESTATED>
<MULTIPLIER> 1,000
       
                             
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                             JAN-01-1997
<PERIOD-END>                               SEP-30-1997
<CASH>                                          55,877
<SECURITIES>                                    65,006
<RECEIVABLES>                                    9,256
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                               138,385
<PP&E>                                          48,003
<DEPRECIATION>                                  16,800
<TOTAL-ASSETS>                                 187,066
<CURRENT-LIABILITIES>                           44,471
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                            25
<OTHER-SE>                                     142,146
<TOTAL-LIABILITY-AND-EQUITY>                   187,066
<SALES>                                              0
<TOTAL-REVENUES>                                62,649
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                51,027
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                  4,145
<INCOME-TAX>                                       313
<INCOME-CONTINUING>                              3,832
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     3,832
<EPS-PRIMARY>                                     0.16
<EPS-DILUTED>                                     0.15